Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Bristol-Myers Squibb Co BMY

Healthcare
Bristol-Myers Squibb Company is a biopharmaceutical company engaged in the discovery, development and delivering advanced medicines that help patients prevail over serious diseases. It offers products for various therapeutic classes, which includes oncology, hematology, immunology, cardiovascular and neuroscience. Its pharmaceutical products include chemically synthesized or small molecule... see more

Recent & Breaking News (NYSE:BMY)

Bristol-Myers Squibb’s ORENCIA (abatacept) Receives FDA Approval for Treatment of Active Psoriatic Arthritis (PsA) in Adults

Business Wire July 6, 2017

Phase 3 Study Evaluating the Safety and Efficacy of Adjuvant Opdivo in Resected High-Risk Melanoma Patients Meets Primary Endpoint

Business Wire July 5, 2017

Breakfast Technical Briefing on Drug Makers Stocks -- Bristol Myers Squibb, Eli Lilly, AstraZeneca, and Sanofi

PR Newswire July 5, 2017

Modern Family Star Eric Stonestreet Challenges Americans to Support the Cancer Community and Learn about Immuno-Oncology Research Through Ready. Raise. Rise.

Business Wire June 28, 2017

A Surprisingly Clean, Straightforward Approval Gives Portola Pharma Shares A Shot Of Upside

Benzinga.com  June 26, 2017

Four-Year Follow-up with Empliciti (elotuzumab) Plus Lenalidomide/Dexamethasone (ELd) in Patients with Advanced Multiple Myeloma Shows Long-term Efficacy in ELOQUENT-2 Trial

Business Wire June 24, 2017

Wall Street's M&A Chatter From June 21: Staples-Sycamore Partners, Diageo-Casamigos, Bristol-Myers, Acadia Pharma

Benzinga.com  June 22, 2017

S&P 500 Buybacks Fall 17.5% Year-over-Year to $133.1 Billion for Q1 2017

PR Newswire June 21, 2017

Bristol-Myers Squibb Announces the Expiration of its Cash Tender Offer

Business Wire June 21, 2017

Bristol-Myers Squibb Announces the Pricing Terms of its Cash Tender Offer For Any and All of Certain of its Outstanding Debt Securities

Business Wire June 20, 2017

Extended Follow-Up Data Evaluating Opdivo (nivolumab) Shows Durable Response in Adult Patients with Relapsed or Progressed Classical Hodgkin Lymphoma

Business Wire June 16, 2017

Bristol-Myers Squibb to Sell Manufacturing Facility in Swords, Ireland to SK Biotek Co., Ltd.

Business Wire June 16, 2017

Seattle Genetics and Bristol-Myers Squibb Highlight Interim Phase 1/2 Data Evaluating Combination of ADCETRIS® (Brentuximab Vedotin) and Opdivo® (Nivolumab) in Relapsed Hodgkin Lymphoma at the International Conference on Malignant Lymphoma

Business Wire June 15, 2017

Bristol-Myers Squibb Announces Cash Tender Offer For Any and All of Certain of Its Outstanding Debt Securities

Business Wire June 14, 2017

Bristol-Myers Squibb To Present New Research Related to the Treatment of Rheumatoid Arthritis Patients With Highly Active, Progressive Disease at the Annual European Congress of Rheumatology (EULAR 2017)

Business Wire June 14, 2017

Bristol-Myers Squibb Announces Dividend

Business Wire June 13, 2017

Bristol-Myers Squibb to Announce Results for Second Quarter 2017 on July 27

Business Wire June 12, 2017

Bristol-Myers Squibb Announces Availability of New ORENCIA® (abatacept) Subcutaneous Administration Option for Patients 2 Years of Age and Older with Moderately to Severely Active Polyarticular Juvenile Idiopathic Arthritis (JIA)

Business Wire June 8, 2017

Les données provenant de l'essai clinique portant sur la combinaison d'Epacadostat et d' Opdivo® (nivolumab) démontrent des réponses cliniques durables chez les patients atteints d'un mélanome et d'un cancer...

Business Wire June 7, 2017

Bristol-Myers Squibb to Take Part in Goldman Sachs 38th Annual Global Healthcare Conference

Business Wire June 7, 2017